ciglitazone has been researched along with Hyperhomocysteinemia in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mishra, PK | 1 |
Tyagi, N | 1 |
Sen, U | 1 |
Joshua, IG | 2 |
Tyagi, SC | 2 |
Reddy, HK | 1 |
Koshy, SK | 1 |
Wasson, S | 1 |
Quan, EE | 1 |
Pagni, S | 1 |
Roberts, AM | 1 |
2 other studies available for ciglitazone and Hyperhomocysteinemia
Article | Year |
---|---|
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.
Topics: Animals; Antioxidants; Cardiomyopathies; Cyclic N-Oxides; Diabetes Complications; Diabetes Mellitus, | 2010 |
Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes.
Topics: Animals; Collagen; Coronary Artery Disease; Coronary Vessels; Diabetes Complications; Diabetes Melli | 2006 |